Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) Chief Financial Officer Matthew Buckhalter executed a sequence of stock sales totaling 36,030 shares of common stock over three trading days in mid-February 2026, generating $266,097 in proceeds.
According to transaction details, the first tranche occurred on February 17, when Buckhalter sold 9,351 shares at a weighted average price of $7.6451, with trade prices in that session spanning $7.47 to $7.97. The following day, February 18, he sold 13,167 shares at a weighted average of $7.3829, with individual trades ranging from $7.175 to $7.53. The final set of sales took place on February 19, when he sold 13,512 shares at a weighted average price of $7.2082, with prices in that session between $7.06 and $7.29.
The company noted that these dispositions were made to cover tax obligations associated with the vesting of equity awards. After completing the sales, Buckhalter retains direct ownership of 529,243 shares of Aveanna common stock.
Market context and recent performance
The insider sales occurred while Aveanna's share price has shown mixed recent performance. The stock has declined 6.4% over the last week and is down 9.2% year-to-date, while remaining up 54% on a 12-month basis. Separately, an InvestingPro analysis cited in company materials indicates the stock appears undervalued at current levels, with additional detail available to subscribers of that service.
Company guidance and analyst responses
Corporate updates around the same period included an upward revision to Aveanna's 2025 financial outlook. The company raised full-year 2025 revenue guidance to a range of $2.425 billion to $2.445 billion, up from a previous outlook of more than $2.375 billion. Likewise, 2025 adjusted EBITDA expectations were increased to $318 million to $322 million, versus an earlier projection of over $300 million.
Aveanna also introduced 2026 guidance, which management said exceeded consensus expectations during an industry event.
In response to the guidance and other company disclosures, a number of brokerages adjusted price targets while preserving ratings. UBS and RBC Capital raised their targets to $10 and $11, respectively, without altering their existing ratings. Raymond James lifted its price target to $13, citing a more favorable Home Health Final Rule and an improved review of debt-paydown timing. William Blair initiated coverage with an Outperform rating.
Implications
The reported insider selling was explicitly linked to tax liabilities from equity vesting rather than a stated change in personal views on the company. At the same time, the company’s upgraded revenue and EBITDA outlook for 2025 and the introduction of 2026 guidance have prompted several analysts to increase price targets and one firm to begin coverage with an Outperform stance.
Observers will likely weigh the tax-driven insider sales alongside the upgraded guidance and analyst reactions when assessing near-term sentiment around the shares.